A number of targeting agents have been evaluated for the treatment of PC, such as tyrosine kinase inhibitors (e.g., erlotinib [8]), poly(ADP-ribose)polymerase (PARP) inhibitors (e.g., olaparib [9]), and monoclonal antibodies (mAbs; e.g., bevacizumab targeting vascular endothelial growth factor (VEGF) [10] and cetuximab targeting epidermal growth factor receptor (EGFR) [11]). The gene discussed is EGFR; the disease is pachyonychia congenita.